A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
作者： Roy S. Herbst , Michael S. Gordon , Gregg Daniel Fine , Jeffrey Alan Sosman , Jean-Charles Soria
DOI: 10.1200/JCO.2013.31.15_SUPPL.3000
关键词:
摘要: … Pts with PD-L1–positive tumors (from archival samples) showed an ORR of 39% (13/33) and a PD rate of 12% (4/33). In contrast, patients with PD-L1–negative tumors showed an ORR …
medsci.cn参考文章(0)